Investor
Investor relations
We are committed to providing all shareholders and potential investors with consistent, transparent, and relevant financial information. This section offers key insights into Lifecare.
Join our journey
Lifecare is a Norwegian med-tech company developing sensors to measure and monitor biomarkers. We focus on diabetes, aiming to bring the next generation of continuous glucose monitoring (GCM) systems to improve diabetes management for humans and pets.
Lifecare as an investment
The GCM market (for humans) surpassed $10 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8-13% until 2030. Lifecare’s technology is proprietary and patented, and has undergone extensive laboratory testing, as well as controlled animal trials. The company is in the clinical trial phase and successfully completed the first human study of its glucose sensor in 2023. We expect to launch our GCM sensor in the pet market in 2025 and aim for CE approval for the human market in 2026.
Stock exchange notices
IR contacts
